期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

三氧化二砷对CD4＋T淋巴细胞免疫功能的调节作用 被引量：3

原文传递
导出
摘要 作为治疗急性早幼粒细胞白血病（APL）的经典药物，近年来三氧化二砷（As2O3）在实体肿瘤和一些自身免疫性疾病中的作用备受关注。以往研究认为，As2O3治疗白血病等肿瘤性疾病的作用机制主要包括促进细胞分化、诱导凋亡和抑制肿瘤血管生成等。目前发现，As2O3不仅是细胞毒性抗肿瘤药物，还具有免疫调节作用。现将As2O3免疫调节作用的研究进展综述如下。
作者 张昊 郑一宁 梅轶芳 张志毅
机构地区 哈尔滨医科大学附属第一医院风湿免疫科
出处 《中华医学杂志》 CAS CSCD 北大核心 2014年第11期875-876,共2页 National Medical Journal of China
基金 国家自然科学基金（81273291）
关键词 免疫调节作用 三氧化二砷 淋巴细胞免疫功能 CD4+T 急性早幼粒细胞白血病 抑制肿瘤血管生成 AS2O3 自身免疫性疾病
分类号 R730.5 [医药卫生—肿瘤]
  • 相关文献

参考文献16

  • 1Chen SJ,Zhou GB,Zhang XW,et al.Froman old remedy to amagic bullet:molecular mechanisms underlying the therapeuticeffects of arsenic in fighting leukemia[J].Blood,2011,117;6425-6437.
  • 2Zhang XW,Yan XJ,Zhou ZH,et al.Arsenic trioxide controls thefate of the PML-RARalpha oneoprotein by directly binding PML[J].Science,2010,328:240-243.
  • 3徐雪,薛愉,邹和建.白细胞介素-17／Th17细胞与血管炎性疾病[J].中华风湿病学杂志,2012,16(3):209-211. 被引量：2
  • 4Belkaid Y.Regulatory T cells and infection:a dangerous necessity[J].Immunol,2007,7:875-888.
  • 5Bobe P,Bonardelle D,Benihoud K,et al.Arsenic trioxide:apromising novel therapeutic agent for lymphoproliferative andautoimmune syndromes in MRL/lpr mice[J].Blood,2006,108:3967-3975.
  • 6Singer M,Trugnan C,Chelbi-Alix MK.Arsenic trioxide reduces 2,4,6-trinitrobenzene sulfonic acid-induced murine colitis via nuclearfactor-kappaB down-regulation and caspase-3 activation[J].Innate Immun,2011,17:365-374.
  • 7Kavian N,Marut W,Servettaz A,et al.Arsenic trioxide preventsmurine sclerodermatous graft-versus-hostdisease[J].J Immunol,2012,188:5142-5149.
  • 8Cho Y,Ahn KH,Back MJ.Age-Related Effects of SodiumArsenite on Splenocyte Proliferation and Th1/Th2 CytokineProduction[J].Arch Pharm Res,2012,35:375-382.
  • 9强孚勇,嘉婷,张挺,孙莉,朱小春.三氧化二砷对大鼠自身免疫性葡萄膜炎疗效的初步观察[J].基础医学与临床,2011,31(12):1351-1357. 被引量：3
  • 10Yan S,Zhang QY,Zhou B,et al.Arsenic Trioxide Attenuated theRejection of Major Histocompatibility Complex Fully-MismatchedCardiac Allografts in Mice[J].Transplantat Proc,2009,41:1855-1858.

二级参考文献30

  • 1Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother, 2005, 54(8) :721-728.
  • 2Lepage S, Lapointe R. Melanosomal targeting sequences from gp100 are essential for MHC class II-restricted endogenous epitope presentation and mobilization to endosomal compartments. Cancer Res, 2006, 66(4) :2423-2432.
  • 3Robila V, Ostankovitch M, Altrich-Vanlith ML, et al. MHC class II presentation of gp100 epitopes in melanoma cells requires the function of conventional endosomes and is influenced by melanosomes. J Immunol, 2008, 181 ( 11 ) :7843-7852.
  • 4Yoon SH, Yun SO, Park JY, et al. Selective addition of CXCR3^+ CCR4-CD4^+ Th1 cells enhances generation of cytotoxic T cells by dendritic cells in vitro. Exp Mol Med, 2009, 41(3) :161-170.
  • 5Allam M, Julien N, Zacharie B, et al. Enhancement of Thl type cytokine production and primary T cell activation by PBI-1393. Clin Immunol, 2007, 125(3) :318-327.
  • 6Hanson HL, Kang SS, Norian LA, et al. CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8 ^+ T cell precursors. J Immunol, 2004, 172(7) :4215- 4224.
  • 7Lapteva N, Seethammagari MR, Hanks BA, et al. Enhanced activation of human dendritic cells by inducible CD40 and Toll- like receptor-4 ligation. Cancer Res, 2007, 67(21 ) :10528-10537.
  • 8Huang H, Hao S, Li F, et al. CD4+ Thl cells promote CD8 + Tcl cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acqvired pMHC I complexes. Immunology, 2007, 120(2) :148-159.
  • 9Yu P, Fu YX. Tumor-infiltrating T lymphocytes:friends or foes? Lab Invest, 2006, 86(3), 231-245.
  • 10Oh S, Perera LP, Terabe M, et al. IL-15 as a mediator of CD4^+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis. Proc Natl Acad Sci U S A, 2008, 105(13) :5201-5206.

共引文献8

同被引文献20

引证文献3

二级引证文献16

中华医学杂志
2014年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部